Antibody therapy for COVID-19.
Antibody therapy for COVID-19.
复制标题
DOI：
10.1097/aci.0000000000000787
复制
发表时间：
2021-12-01
影响因子：
2.8
通讯作者：
Pan-Hammarström Q
中科院分区：
文献类型：
--
作者：
Hammarström L;Marcotte H;Piralla A;Baldanti F;Pan-Hammarström Q
提供严重急性呼吸系统综合征冠状病毒2型感染的抗体治疗现状的最新信息，该抗体治疗在很短的时间内取得了巨大进展。经典被动免疫治疗（血浆治疗、超免疫免疫球蛋白[IgG]制剂）的临床效果有限，而单克隆抗体治疗，如果在疾病过程的早期开始，则显示出有希望的结果。尽管在COVID-19患者中的抗体治疗仍有待充分探索，但目前针对刺突蛋白受体结合结构域的IgG单克隆抗体的组合似乎提供了最佳形式的抗体治疗，免疫球蛋白A二聚体和免疫球蛋白M五聚体也显示出有希望的初步治疗结果。
To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results. Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.